Fig. 1From: Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective studyThe overall survival in the eribulin and non-eribulin groups (A), eribulin group of patients who received eribulin at an early line (first or second) and non-eribulin group (B) and eribulin group of patients who received eribulin at a late line (third or later) and non-eribulin group (C). CI: confidence interval, OS: Overall survivalBack to article page